I’m questioning if a raise would even have an adverse affect on price at this point. Whatever dilution it would cause would seemingly be more than offset by the confidence that we’d then be fully funded through FDA submission.
I think I will dollar cost average ghrough 2019. I give up trying to time it. The analysts say it's undervalued, we've known that for years...still could drop below $1 this year BUT it seems nasdaq has brought some degree of correlation between SP and the company's actions. This bodes well for the future if timeline is adhered to by big mac.